CEO Richard Fair was paid $11,918,926 in fiscal year 2025 (SEC filing 0001193125-26-182045 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$11,918,926 Richard Fair total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Richard Fair | $38,077 | $0 | $0 | $11,880,138 | $0 | $0 | $711 | $11,918,926 |
| President and Chief Executive Officer | ||||||||
| Sam Kintz | 624,154 | 0 | 0 | 7,952,553 | 316,800 | 0 | 15,140 | 8,908,647 |
| Former President and Chief Executive Officer | ||||||||
| Helen Collins | 523,000 | 0 | 0 | 2,775,279 | 188,280 | 0 | 15,140 | 3,501,699 |
| Chief Medical Officer | ||||||||
| Ben Hohl | 480,000 | 0 | 0 | 2,775,279 | 172,800 | 0 | 15,094 | 3,443,173 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Richard Fair | $11,918,926 | — | — | — |
| Sam Kintz | 8,908,647 | 5,461,660 | — | ↑ +3,446,987 |
| Helen Collins | 3,501,699 | 2,771,410 | — | ↑ +730,289 |
| Ben Hohl | 3,443,173 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Enliven Therapeutics, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ELVN reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ELVN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELVN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Fair | Option | 875,000 | 18.77 | — |
| Ben Hohl | Option | 60,084 | 22.75 | — |
| Helen Collins | Option | 60,084 | 22.75 | — |
| Helen Collins | Option | 100,209 | 14.85 | — |
| Helen Collins | Option | 171,000 | 22.47 | — |
| Ben Hohl | Option | 171,000 | 22.47 | — |
| Ben Hohl | Option | 100,209 | 14.85 | — |
The Company provides cash incentive compensation to its named executive officers based on their meeting of one or more corporate performance objectives, with the board selecting challenging goals that are achievable only by strong performance. The compensation committee reviews CEO recommendations and market data to determine total compensation, focusing on company results, individual contribution, and goal achievement.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Richard Heyman, Ph.DIndependent · Board Chair · Compensation · Not standing for re-election | $46,000 | — | $365,000 | — | — | $411,000 |
| Jake Bauer, M.B.AIndependent · Audit (Chair) · Compensation | 61,000 | — | 324,985 | — | — | 385,985 |
| Andrew PhillipsIndependent | 57,500 | — | 324,985 | — | — | 382,485 |
| Mika Derynck, M.DIndependent · Audit · Nominating and Corporate Governance | 52,500 | — | 324,985 | — | — | 377,485 |
| Rishi Gupta, J.DIndependent · Audit · Compensation (Chair) | 52,000 | — | 324,985 | — | — | 376,985 |
| Rahul Ballal, Ph.DIndependent | 40,000 | — | 324,985 | — | — | 364,985 |
| Lori Kunkel, M.DIndependent · Nominating and Corporate Governance | 45,000 | — | 243,735 | — | — | 288,735 |
| Richard Fair, M.B.AEmployee director | — | — | — | — | — | 0 |
| Scott Garland, M.B.AIndependent · Nominating and Corporate Governance (Chair) · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $325,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $354,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $354,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Enliven Therapeutics, Inc. | 2025 | Richard Fair | $38,077 | $0 | $11,880,138 | $0 | $11,918,926 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Richard Fair | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Executive Compensation”. As printed: 11,918,926. Filing ↗machine: r4 · c22 · span 356110–356120 |
| 2 | Section 01, Sam Kintz | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Executive Compensation”. As printed: 8,908,647. Filing ↗machine: r5 · c22 · span 358693–358702 |
| 3 | Section 01, Helen Collins | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Executive Compensation”. As printed: 3,501,699. Filing ↗machine: r7 · c22 · span 363861–363870 |
| 4 | Section 01, Ben Hohl | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Executive Compensation”. As printed: 3,443,173. Filing ↗machine: r10 · c22 · span 370212–370221 |
| 5 | Section 08, Richard Heyman, Ph.D | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 411,000. Filing ↗machine: span 269612–269660 |
| 6 | Section 08, Jake Bauer, M.B.A | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 385,985. Filing ↗machine: span 265327–265375 |
| 7 | Section 08, Andrew Phillips | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 382,485. Filing ↗machine: span 272462–272510 |
| 8 | Section 08, Mika Derynck, M.D | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 377,485. Filing ↗machine: span 266763–266811 |
| 9 | Section 08, Rishi Gupta, J.D | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 376,985. Filing ↗machine: span 268173–268221 |
| 10 | Section 08, Rahul Ballal, Ph.D | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 364,985. Filing ↗machine: span 263916–263964 |
| 11 | Section 08, Lori Kunkel, M.D | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 288,735. Filing ↗machine: span 271022–271070 |
| 12 | Section 08, Richard Fair, M.B.A | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 08, Scott Garland, M.B.A | DEF 14A | 2026-04-27 | 0001193125-26-182045 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 354,000 + equity 0 + all other 0 = 354,000, summed across the director compensation table rows.machine: formula: Σ = 354,000 |
| 16 | Enliven Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182045 | CEO total compensation as printed in Enliven Therapeutics, Inc.'s own proxy. As printed: 11,918,926. Filing ↗machine: r4 · c22 · span 356110–356120 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat